ANI Pharmaceuticals Signals Strong Growth in 2025 Call

Ani Pharmaceuticals ((ANIP)) has held its Q4 earnings call. Read on for the main highlights of the call.

ANI Pharmaceuticals’ latest earnings call struck an optimistic tone, as management highlighted record 2025 results, accelerating momentum in key franchises, and strong cash generation supporting future growth. While executives acknowledged margin pressure, higher royalties, and heavier spending to fund a rare disease push, they framed these as deliberate investments and temporary headwinds against a backdrop of robust, broad-based expansion.

Record 2025 Financial Performance

ANI posted full-year 2025 revenue of $883.4 million, a 44% jump versus the prior year, underscoring the power of its diversified model. Adjusted non‑GAAP EBITDA climbed 47% to $229.8 million, while adjusted non‑GAAP diluted EPS surged to $7.89 from $5.20, signaling strong operating leverage despite rising costs.

Cortrophin Gel as a Growth Engine

Cortrophin Gel remained the clear star, with 2025 net revenue of $347.8 million, up 76% year over year, and Q4 revenue of $111.4 million, up 88%. Management expects Cortrophin to grow another 55%–65% in 2026 to $540–$575 million, cementing its role as the primary driver of the rare disease transformation.

Generics Segment Delivers Steady Gains

The generics business also delivered, generating $384.1 million in 2025 revenue, up 28% year over year, with Q4 generics sales of $100.8 million matching that growth rate. Management emphasized a continued cadence of 10–15 new launches annually, positioning the generics segment as a reliable cash engine that funds strategic investments.

Fourth Quarter Momentum Confirms Trajectory

Total Q4 revenue reached $247.1 million, up 30% from the prior-year quarter, reflecting strong demand across both brands and generics. Adjusted non‑GAAP EBITDA rose 31% to $65.4 million and adjusted diluted EPS increased to $2.33 from $1.63, reinforcing that growth is translating into earnings.

Robust Cash Generation and Balance Sheet Flexibility

Year-end unrestricted cash grew to $285.6 million, up $140.7 million from a year earlier, backed by $185.2 million in operating cash flow. This liquidity gives ANI room to reinvest in its rare disease strategy and pursue disciplined M&A without overextending the balance sheet.

Deleveraging Progress Despite Remaining Debt Load

ANI closed 2025 with $629.1 million of principal debt, but leverage metrics improved meaningfully as earnings expanded. Gross leverage stood at 2.7x and net leverage at 1.5x adjusted EBITDA, providing headroom for future deals even as the company acknowledges that the remaining debt still influences capital allocation choices.

Clear 2026 Growth Outlook

Management laid out 2026 guidance calling for $1.055–$1.115 billion in revenue, implying roughly 19%–26% growth versus 2025 at a midpoint near 23%. Adjusted EBITDA is expected to reach $275–$290 million and adjusted EPS $8.83–$9.34, signaling confidence in continued top‑ and bottom‑line expansion.

Rare Disease Transformation Strategy

The company reiterated its ambition to become a leading rare disease player, anchored by Cortrophin and a growing presence in acute gout flares. Plans include a 90‑person organization dedicated to gout and a 150‑patient Phase IV study, alongside broader R&D spending designed to deepen the evidence base and expand prescriber adoption.

Commercial and Product Enhancements

To drive uptake, ANI launched a Cortrophin prefilled syringe last April that simplifies administration and supports patient convenience. The company also highlighted that ophthalmology volumes more than doubled year over year in Q4, a sign that commercial execution is gaining traction across key specialties.

Payer Coverage Tailwinds for ILUVIEN

In retina, a critical milestone came as all seven Medicare Administrative Contractors updated policies to cover ILUVIEN for both CIU/NIUPS and DME indications. The largest commercial insurers with ILUVIEN‑specific policies have also aligned coverage with both uses, improving the long‑term access foundation for this asset.

Margin Pressure from Product Mix and Royalties

Despite the growth, margins remain under pressure as higher‑royalty products take a larger share of sales and some brand revenues soften. Q4 non‑GAAP gross margin slipped to 59.6%, about 400 basis points lower year over year, while full‑year margin edged down to 61.6%, and 2026 guidance of 59.3%–60.3% points to continued headwinds.

Royalty Burden at the High End

Cortrophin’s success pushed it into the highest royalty tier in 2025, and management expects a blended royalty rate in the high‑20% range for 2026, with a cap near 30%. This royalty drag will weigh on gross margins unless offset by scale, mix improvements, or further efficiencies, making cost discipline increasingly important.

Higher Operating Spend to Fuel Expansion

Non‑GAAP SG&A expenses climbed 28% in Q4 and 46% for the full year as ANI expanded its ophthalmology sales team and poured money into rare disease initiatives. The planned 90‑person gout build‑out, mostly in sales and support roles, will add roughly $50 million in operating expense at the midpoint and is not expected to fully pay off until 2027.

Seasonality and Access Headwinds in Early 2026

Management warned that Q1 2026 will show a sequential revenue dip as Cortrophin’s share of annual sales falls to about 13%–14% versus 15% in 2025. Longer insurance reverifications and winter‑related office closures are expected to weigh on early‑year volumes, though the company anticipates a recovery by March and a stronger second half.

Funding Constraints for Retina Patient Support

ANI noted that patient assistance foundations had limited funding in 2025, reducing co‑pay support for Medicare retina patients and complicating ILUVIEN access. The company is working through specialty pharmacies to mitigate the impact, but management acknowledged that this dynamic remains a meaningful barrier for some patients.

Execution and Timing Risks Around Investments

The new 90‑person gout team is scheduled to launch mid‑2026, with management expecting noticeable volume contributions in the back half of the year and full productivity in 2027. Ongoing Phase IV and other clinical studies should bolster adoption over time, but they do not remove the near‑term execution and timing risks associated with such a large commercial build‑out.

Forward-Looking Guidance and Outlook

For 2026, ANI reaffirmed its targets for net revenue of $1.055–$1.115 billion, with rare disease products making up around 60% of the total and Cortrophin contributing $540–$575 million. The company projects ILUVIEN revenue of $78–$83 million, adjusted EBITDA of $275–$290 million, adjusted EPS between $8.83 and $9.34, and expects Q4 to be the strongest quarter as a new gout team ramps.

ANI’s earnings call painted a picture of a company in the midst of a profitable transformation, with rare disease assets increasingly at the center of its story. While margin pressures, royalty obligations, funding constraints, and execution risks remain, investors heard a management team confident that record 2025 results and clear 2026 growth plans provide a solid base for further value creation.